Top

World Journal of Urology

Published in:

01-08-2017 | Topic Paper

Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?

Authors: Jan Oldenburg, Klaus-Peter Dieckmann

Published in: World Journal of Urology | Issue 8/2017

Abstract

Introduction

In 1979, the Copenhagen group around Dr. Skakkebaek introduced contralateral biopsy in patients with testicular germ cell tumour (GCT) as a means of early diagnosing a contralateral testicular tumour (Berthelsen et al. in Br Med J 2(6186):363–364, 1). Although the rationale of contralateral biopsies is based on much of scientific evidence, no issue regarding the management of GCTs has been more controversial than the issue of contralateral biopsies (Heidenreich in BJU Int 104(9 Pt B):1346–1350, 2; Grigor and Rorth in Eur Urol 23(1):129–135, 3). A poll conducted during the GCT Consensus Meeting in Berlin 2011 revealed that 43 % of 60 leading experts would not recommend a contralateral biopsy and only 13.7 % would do the biopsy in all cases with GCT (Beyer et al. in Ann Oncol 24(4):878–888, 4). Likewise, the European Association of Urology and the European Society of Medical Oncology offer only weak recommendations with respect to contralateral biopsies in their guidelines of testicular cancer (Albers et al. in Eur Urol 68(6):1054–1068, 5; Oldenburg et al. in Ann Oncol 24(Suppl 6):vi125–vi132, 6).

Conclusion

This review summarizes contemporary knowledge regarding contralateral biopsies to provide professionals caring for GCT patients with sufficient information to decide for or against the procedure in clinical practice.

Berthelsen JG, Skakkebaek NE, Mogensen P et al (1979) Incidence of carcinoma in situ of germ cells in contralateral testis of men with testicular tumours. Br Med J 2(6186):363–364CrossRefPubMedPubMedCentral

Heidenreich A (2009) Contralateral testicular biopsy in testis cancer: current concepts and controversies. BJU Int 104(9 Pt B):1346–1350CrossRefPubMed

Grigor KM, Rorth M (1993) Should the contralateral testis be biopsied? Round table discussion. Eur Urol 23(1):129–135PubMed

Beyer J, Albers P, Altena R et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24(4):878–888CrossRefPubMed

Albers P, Albrecht W, Algaba F et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054–1068CrossRefPubMed

Oldenburg J, Fossa SD, Nuver J et al (2013) Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi125–vi132CrossRefPubMed

Skakkebaek NE (1972) Possible carcinoma-in-situ of testis. Lancet 2(7776):516–517CrossRefPubMed

Rajpert-De ME, Nielsen JE, Skakkebaek NE et al (2015) Diagnostic markers for germ cell neoplasms: from placental-like alkaline phosphatase to micro-RNAs. Folia Histochem Cytobiol 53(3):177–188CrossRef

Emerson RE, Ulbright TM (2010) Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. Pathology 42(4):344–355CrossRefPubMed

10.

Oosterhuis JW, Stoop H, Dohle G et al (2011) A pathologist’s view on the testis biopsy. Int J Androl 34(4 Pt 2):e14–e19CrossRefPubMed

11.

Skakkebaek NE, Berthelsen JG, Giwercman A et al (1987) Carcinoma-in situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 10(1):19–28CrossRefPubMed

12.

Berthelsen JG, Skakkebaek NE (1981) Value of testicular biopsy in diagnosing carcinoma in situ testis. Scand J Urol Nephrol 15(3):165–168CrossRefPubMed

13.

Loy V, Wigand I, Dieckmann KP (1990) Incidence and distribution of carcinoma in situ in testes removed for germ cell tumour: possible inadequacy of random testicular biopsy in detecting the condition. Histopathology 16(2):198–200CrossRefPubMed

14.

Nistal M, Codesal J, Paniagua R (1989) Carcinoma in situ of the testis in infertile men. A histological, immunocytochemical, and cytophotometric study of DNA content. J Pathol 159(3):205–210CrossRefPubMed

15.

Dieckmann KP, Skakkebaek NE (1999) Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 83(6):815–822CrossRefPubMed

16.

Petersen PM, Giwercman A, Daugaard G et al (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in situ in the testis. J Clin Oncol 20(6):1537–1543CrossRefPubMed

17.

Bang AK, Petersen JH, Petersen PM et al (2009) Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys 75(3):672–676CrossRefPubMed

18.

Hoei-Hansen CE, Holm M, Rajpert-De ME et al (2003) Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 200(3):370–374CrossRefPubMed

19.

Holstein AF, Lauke H (1996) Histologic diagnostics of early testicular germ-cell tumor. Int J Urol 3(3):165–172CrossRefPubMed

20.

Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14(12):3126–3132CrossRefPubMed

21.

Harland SJ, Cook PA, Fossa SD et al (1993) Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report. Eur Urol 23(1):115–118PubMed

22.

Huyghe E, Muller A, Mieusset R et al (2007) Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol 52(6):1710–1716CrossRefPubMed

23.

Moul JW (2007) Timely diagnosis of testicular cancer. Urol Clin N Am 34(2):109–117CrossRef

24.

Daugaard G, Giwercman A, Skakkebaek NE (1996) Should the other testis be biopsied? Semin Urol Oncol 14(1):8–12PubMed

25.

Rajpert-De ME, Jorgensen N, Brondum-Nielsen K et al (1998) Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. APMIS 106(1):198–204

26.

van der Zwan YG, Biermann K, Wolffenbuttel KP et al (2015) Gonadal maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. Eur Urol 67(4):692–701CrossRefPubMed

27.

Elzinga-Tinke JE, Dohle GR, Looijenga LH (2015) Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis. Asian J Androl 17(3):381–393PubMedPubMedCentral

28.

Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G et al (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16(6):863–868CrossRefPubMed

29.

Prym C, Lauke H (1994) Carcinoma-in situ of the human testis: tumour cells are distributed focally in the seminiferous tubules. Andrologia 26(4):231–234CrossRefPubMed

30.

van Casteren NJ, Boellaard WP, Dohle GR et al (2008) Heterogeneous distribution of ITGCNU in an adult testis: consequences for biopsy-based diagnosis. Int J Surg Pathol 16(1):21–24CrossRefPubMed

31.

Kier MG, Lauritsen J, Almstrup K et al (2015) Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study. Ann Oncol 26(4):737–742CrossRefPubMed

32.

Kliesch S, Thomaidis T, Schutte B et al (2003) Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS 111(1):70–74CrossRefPubMed

33.

Dieckmann KP, Kulejewski M, Pichlmeier U et al (2007) Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 51(1):175–183CrossRefPubMed

34.

Ruf CG, Gnoss A, Hartmann M et al (2015) Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia. Andrology 3(1):92–98CrossRefPubMed

35.

Dieckmann KP, Kulejewski M, Heinemann V et al (2011) Testicular biopsy for early cancer detection–objectives, technique and controversies. Int J Androl 34(4 Pt 2):e7–e13CrossRefPubMed

36.

Jacobsen R, Bostofte E, Engholm G et al (2000) Risk of testicular cancer in men with abnormal semen characteristics: cohort study. Br Med J 321(7264):789–792CrossRef

37.

Walsh TJ, Croughan MS, Schembri M et al (2009) Increased risk of testicular germ cell cancer among infertile men. Arch Intern Med 169(4):351–356CrossRefPubMedPubMedCentral

38.

Hotaling JM, Walsh TJ (2009) Male infertility: a risk factor for testicular cancer. Nat Rev Urol 6(10):550–556CrossRefPubMed

39.

Nistal M, Paniagua R (1999) Testicular biopsy. Contemporary interpretation. Urol Clin N Am 26(3):555–593CrossRef

40.

Winstanley AM, Mikuz G, Debruyne F et al (2004) Handling and reporting of biopsy and surgical specimens of testicular cancer. Eur Urol 45(5):564–573CrossRefPubMed

41.

Dieckmann KP, Loy V (2003) False-negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN)—an update. Eur Urol 43(5):516–521CrossRefPubMed

42.

Dieckmann KP, Heinemann V, Frey U et al (2005) How harmful is contralateral testicular biopsy? An analysis of serial imaging studies and a prospective evaluation of surgical complications. Eur Urol 48(4):662–672CrossRefPubMed

43.

von der Maase H (2005) Is a contralateral testicular biopsy in patients with unilateral germ cell testicular cancer indicated as a routine procedure? Acta Oncol 44(6):523–525CrossRefPubMed

44.

Gillon R (1985) “Primum non nocere” and the principle of non-maleficence. Br Med J (Clin Res Ed) 291(6488):130–131CrossRef

45.

Wilson JMG, Junger G (2016) Principles and practice of screening for disease. World Health Organisation, Geneva

46.

Dieckmann KP (2015) Contralateral biopsies in patients with testicular germ-cell tumour-nuisance or new sense? Ann Oncol 26(4):620–621CrossRefPubMed

47.

Tandstad T, Solberg A, Hakansson U et al (2015) Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncol 54(4):493–499CrossRefPubMed

Title: Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?
Authors: Jan Oldenburg
Klaus-Peter Dieckmann
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1945-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?

Abstract

Introduction

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2017

Residual stones after percutaneous nephrolithotomy: comparison of intraoperative assessment and postoperative non-contrast computerized tomography

Residual tumor resection (RTR)

Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications

Nobel Prize nominees and the rise of urology in Europe around 1900

A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India

Platinum-refractory germ cell tumors: an update on current treatment options and developments